View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
September 27, 2018

Refocused Moderna Therapeutics barrels toward historic IPO

Since its launch in 2010, Moderna Therapeutics has become as famous for its valuation as it has for the secrecy around its messenger RNA (mRNA) technology. Despite remaining privately held and relatively tight-lipped about data, the company has enjoyed a flourishing channel of funding, raising over $1.6B in equity and $1B in partnerships over recent years, capped by a recent $125M Series H round from Merck.

By GlobalData Healthcare

Since its launch in 2010, Moderna Therapeutics has become as famous for its valuation as it has for the secrecy around its messenger RNA (mRNA) technology. Despite remaining privately held and relatively tight-lipped about data, the company has enjoyed a flourishing channel of funding, raising over $1.6B in equity and $1B in partnerships over recent years, capped by a recent $125M Series H round from Merck.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Moderna is now one of the most highly valued startup companies in biotech history with a towering $7.5B price tag. In September, STAT news reported that the Cambridge-based developer may soon take its biggest step out of the shadows yet, targeting an initial public offering (IPO) by the end of 2018. As an intriguing but unproven biotech focused on developing typically low-margin vaccines for infectious diseases, will Moderna be able to justify its lofty valuation?

Moderna spun out from the work of Harvard scientists Derrick Rossi and Tim Springer, growing rapidly after CEO Stéphane Bancel was tapped to helm the company. In 2013, Moderna announced a multi-year collaboration with AstraZeneca on cardiovascular diseases and cancer, which included $240M in upfront payments. From there, funding and partnerships continued to flow, including collaborations with the US Defense Advanced Research Projects Agency (DARPA), Vertex, and Merck.

However, becoming the first company to commercialise an mRNA medicine proved to be challenging. Although the mechanism through which RNA transcript produces proteins in cells is well understood, delivery and side effects of engineered mRNA have been major obstacles for many developers, including Moderna. In early 2017, STAT news reported that Moderna’s therapy for the rare disease Crigler–Najjar syndrome had been delayed indefinitely following safety concerns.

In response to setbacks and growing cynicism from the scientific community, Moderna began to embrace transparency in 2017, publishing eight papers in leading clinical and translational research journals. The company also consolidated its focus on infectious pathogens, announcing nine vaccine programs for diseases ranging from influenza to human metapneumovirus (HMPV).

GlobalData believes that a push into infectious diseases is a rational way to establish proof-of-concept for mRNA therapies, particularly because mRNA vaccines typically require a single dose and are well tolerated. Moreover, Moderna has the opportunity to leverage an optimised mRNA vaccine platform to rapidly address emerging infectious diseases around the globe. The company currently has two Phase I products in its pipeline, for Chikungunya (mRNA-1388) and Zika virus (mRNA-1325).

One of Moderna’s notable products is mRNA-1647, a prophylactic vaccine for cytomegalovirus (CMV). Preclinical studies showed potent neutralising antibody responses in rodents and non-human primates, and mRNA-1647 entered Phase I human testing in late 2017. Key opinion leaders (KOLs) interviewed by GlobalData believe that the CMV vaccine field is ripe for new players, following the Phase III flop of Vical and Astellas’ DNA vaccine ASP0113. To further bolster its chances, Moderna recently brought on Dr. Wellington Sun, former FDA director of the Division of Vaccines and Related Product Applications, to serve as its head of Vaccine Strategy and Regulatory Affairs.

The rest of Moderna’s pipeline includes a dozen candidates spanning oncology, rare diseases, and cardiology. Its lead product is the AstraZeneca-partnered mRNA-8601, which encodes vascular endothelial growth factor-A (VEGF-A) for treatment of cardio-metabolic diseases. Early clinical trials for mRNA-8601 were positive, and in February 2018 the drug became Moderna’s first to enter Phase II testing.

Moderna is hoping to hit on at least one of its 10 products in clinical development, allowing a move into more lucrative spaces like immuno-oncology. However, with growing pressure from rival clinical-stage mRNA companies like CureVac, Moderna’s initial bet on infectious diseases—particularly those with high unmet needs—will likely prove to be a shrewd tactic.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology